Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Agenus has revealed via a Securities and Exchange Commission (SEC) filing that US pharma major Bristol Myers Squibb (NYSE: BMS) was pulling out of a licensing deal. 5 August 2024
Taiwan-based Formosa Pharmaceuticals (6838.TWO) has announced an exclusive licensing agreement with Canadian pharmaceutical company Apotex for the commercialization of APP13007. 5 August 2024
Jade Biosciences (Nasdaq: JAD), a biotechnology company specializing in the development of therapies for autoimmune diseases, has announced the successful closing of an $80 million financing round. 5 August 2024
US rare disease drug focussed company Zevra Therapeutics saw its shares rise nearly 43% to $9.00 in after-hours trading on Friday as it announced a positive development for its arimoclomol. 5 August 2024
BridGene Biosciences is expanding its collaboration with Belgian firm Galapagos (Euronext: GLPG) to advance drug discovery for challenging cancer targets. 2 August 2024
Californian life sciences investor venBio has announced the successful closing of its fifth fund, venBio Global Strategic Fund V, which has raised approximately $528 million. 2 August 2024
Adaptimmune Therapeutics (Nasdaq: ADAP) has received Accelerated Approval from the US Food and Drug Administration (FDA) for Tecelra (afamitresgene autoleucel). 2 August 2024
A change at the top is on the way at Cour Pharmaceuticals, a privately-held US biotech developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases. 1 August 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a final draft guidance (FDG) recommending Brukinsa for MZL. 1 August 2024
IDEAYA Biosciences has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with Chinese biotech Biocytogen Pharmaceuticals. 1 August 2024
Boston, USA-based vaccines company HilleVax has attempted to stem the tide following its announcement of disastrous norovirus trial results last month. 1 August 2024
Tigermed (SZ: 300347), a global clinical research solution provider, has completed a move to boost capabilities in Japan and beyond, with the acquisition of the contract research organization (CRO) Medical Edge. 31 July 2024
Osaka-based Ono Pharmaceutical (TYO: 4502) has added a new collab to a growing list of deals made in 2024, agreeing to work with Systasy Bioscience. 31 July 2024